image
Healthcare - Biotechnology - NASDAQ - CA
$ 0.5181
-6.42 %
$ 44.8 M
Market Cap
-1.7
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ONCY stock under the worst case scenario is HIDDEN Compared to the current market price of 0.518 USD, Oncolytics Biotech Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ONCY stock under the base case scenario is HIDDEN Compared to the current market price of 0.518 USD, Oncolytics Biotech Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ONCY stock under the best case scenario is HIDDEN Compared to the current market price of 0.518 USD, Oncolytics Biotech Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ONCY

image
$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
0 REVENUE
0.00%
-33.8 M OPERATING INCOME
-18.28%
-31.7 M NET INCOME
-14.26%
-27 M OPERATING CASH FLOW
5.21%
-239 K INVESTING CASH FLOW
-1.18%
6.64 M FINANCING CASH FLOW
-79.26%
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-8.02 M NET INCOME
15.99%
-7.85 M OPERATING CASH FLOW
-62.38%
-6 K INVESTING CASH FLOW
81.25%
3.34 M FINANCING CASH FLOW
2030.06%
Balance Sheet Oncolytics Biotech Inc.
image
Current Assets 18.9 M
Cash & Short-Term Investments 15.9 M
Receivables 68 K
Other Current Assets 2.86 M
Non-Current Assets 1.31 M
Long-Term Investments 0
PP&E 1.31 M
Other Non-Current Assets 0
78.97 %14.19 %6.50 %Total Assets$20.2m
Current Liabilities 6.69 M
Accounts Payable 1.09 M
Short-Term Debt 277 K
Other Current Liabilities 5.32 M
Non-Current Liabilities 7.52 M
Long-Term Debt 787 K
Other Non-Current Liabilities 6.73 M
7.65 %37.48 %5.54 %47.38 %Total Liabilities$14.2m
EFFICIENCY
Earnings Waterfall Oncolytics Biotech Inc.
image
Revenue 0
Cost Of Revenue 403 K
Gross Profit -403 K
Operating Expenses 33.8 M
Operating Income -33.8 M
Other Expenses -2.08 M
Net Income -31.7 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)0(403k)(403k)(34m)(34m)2m(32m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Oncolytics Biotech Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -31.7 M
Depreciation & Amortization 424 K
Capital Expenditures -239 K
Stock-Based Compensation 2.72 M
Change in Working Capital 3.54 M
Others 1.65 M
Free Cash Flow -27.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Oncolytics Biotech Inc.
image
ONCY has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Oncolytics Biotech Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. prnewswire.com - 2 weeks ago
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO and CALGARY, AB , April 24, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options. "Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist," said Thomas Heineman, M.D. prnewswire.com - 3 weeks ago
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value. prnewswire.com - 1 month ago
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright. prnewswire.com - 1 month ago
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2024 Results Conference Call March 7, 2025 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chairman of Oncotic's Board of Directors and Interim CEO Tom Heineman - Chief Medical Officer Kirk Look - Chief Financial Officer Christophe Degois - Vice President of Business Development Conference Call Participants Michael Freeman - Raymond James Luis Santos - H.C. Wainwright Operator Good morning, and welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2024 conference call. seekingalpha.com - 2 months ago
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.9 million provides runway through critical milestones into third quarter 2025 Management hosting conference call and webcast this morning at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , March 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024. prnewswire.com - 2 months ago
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 2 months ago
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. prnewswire.com - 2 months ago
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential impact across a range of tumors //Republication of press release issued February 18 th 2025 due to news transmission coverage// SAN DIEGO and CALGARY, AB , Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January. prnewswire.com - 2 months ago
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO and CALGARY, AB , Feb. 18, 2025 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January. prnewswire.com - 2 months ago
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on February 13, 2025 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. prnewswire.com - 3 months ago
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence Search for Chief Executive Officer to commence immediately SAN DIEGO  and  CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Matt Coffey, Ph.D., President and Chief Executive Officer, will not return following a medical leave of absence and ongoing health concerns. prnewswire.com - 3 months ago
8. Profile Summary

Oncolytics Biotech Inc. ONCY

image
COUNTRY CA
INDUSTRY Biotechnology
MARKET CAP $ 44.8 M
Dividend Yield 0.00%
Description Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Contact 322 11th Avenue SW, Calgary, AB, T2R 0C5 https://www.oncolyticsbiotech.com
IPO Date Oct. 5, 2001
Employees 28
Officers Mr. Kirk J. Look C.A., CPA Chief Financial Officer Mr. Christophe Degois Vice President of Business Development Mr. Wayne F. Pisano M.B.A. Interim Chief Executive Officer & Chairman of the Board Dr. Thomas C. Heineman M.D., Ph.D. Chief Medical Officer Ms. Allison Hagerman P.Eng., P.M.P. Vice President of Product Development Jon Patton Director of Investor Relations & Communication Mr. John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. Consultant Ms. Amy Goodowitz Levin B.S.N., R.N. Vice President of Clinical Operations